Anti-infective is a common term used to illustrate any medicine which inhibits the spread of an infectious organism or by killing of an infectious micro-organism inside the body. Anti-infective encompasses of the antibiotics, anthelmintic, antifungal, anti-malarial, anti-tuberculosis agents, anti-protozoals, and the antivirals. The working of anti-infective includes interfering in biomolecular functioning of microbes such as cell wall formation, replication, protein synthesis and many more.
According to study, “Anti-Infective Drugs Global Market Report 2019” the key companies operating in the anti-infective drugs global market are Gilead, GlaxosmithKline Plc., Wockhardt ltd, Boehringer Ingelheim, Roche, Allergen Plc., Abbott Laboratories, Inc., AstraZeneca Plc., Otsuka Pharmaceutical Co. Ltd., Gilead Sciences Inc., Merck & Co. Inc., F. Hoffman-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Pfizer Inc., Sanofi, Johnson & Johnson Services Inc., Bayer AG, Bristol-Myers Squibb Company. The companies have launched a panel of Food and Drug Administration (FDA) approved adapted antibiotics for the treating of a soft tissue infections and acute bacterial skin; these drugs include Sivextro (Tedizolid), Orbactiv (Oritavancin), Dalvance (Dalbavancin), and Zevtera (Ceftobiprole).
Based on the type of drug, anti-infective drugs market is segmented into amebicides, anti-fungal drugs, anthelmintics, anti-bacterial drugs, antimalarial agents, and anti-viral drugs. The anti-fungal drugs include echinocandins (micafungin, caspofungin and anidulafungin), azoles and polyenes. Among them azoles are expected to lead the market owing to high ability of combat systemic fungal infections. Some of the key anti-bacterial drugs are macrolides, B-lactams, tetracycline, quinolones, aminoglycoside and others. Based on route of administration, market is segmented into oral, topical, Intravenous (IV) and others. The oral route of administration holds the largest market share due to strong pipeline and new product development. Based on indication, market is segmented into sepsis, pneumonia, tuberculosis, Methicillin-resistant Staphylococcus Aureus (MRSA), dermatophytosis, candidiasis, aspergillosis, HIV infection, hepatitis virus infection and respiratory virus infection. Based on range, market is segmented into narrow spectrum and broad spectrum. Moreover, based on distribution channel, market is segmented into specialty pharmacy, retail pharmacy, hospital pharmacy and online sales.
The anti-infective drugs global market is driven by high purchasing power for the expensive drugs, and increase in prevalence of target diseases such as STIs, followed by presence of favorable reimbursement policies. The hospital acquired infections, respiratory viruses, growing geriatric population base and increase in collaborative development efforts are some of the other key factors expected to drive the market over the forecast period. Additionally, organizations, such as the Centers for Disease control & Prevention (CDC) and World Health Organization (WHO) are actively involved in spreading consciousness amongst people for the serious implications of infectious diseases and importance of the early treatment. Apart from key drivers, few of factors restraining the market growth include high R&D cost, and development of multi-drug resistant organisms.
The North American region holds the largest market share of anti-infective drugs market owing to awareness among end-users such as clinicians & healthcare professionals followed by the presence of sophisticated healthcare infrastructure in the region. In addition, Asia-Pacific region is expected to witness considerable increase in CAGR over the forecast period due to rise in economic stability, presence of generics companies coupled with increase in disposable income and augmented susceptibility supporting the market growth in the region.
For more information, refer to below link:-
Ankur Gupta, Head Marketing & Communications
Ken Research is a Global aggregator and publisher of Market intelligence, equity and economy reports. Ken Research provides business intelligence and operational advisory in 300+ verticals underscoring disruptive technologies, emerging business models with precedent analysis and success case studies. Serving 70% of fortune 500 companies globally, some of top consulting companies and Market leaders seek Ken Research intelligence to identify new revenue streams, customer/ vendor paradigm and pain points and due diligence on competition. With a network panel list of 5000+ Industry Veterans and experienced 100+ analysts, consultants and research publishers across the globe, Ken Research aid clients in identifying the demand–supply gap, niche segments and challenges in the ecosystem.